Evidence map›Paper›PMID 39161261›Full record

ArticleEnvironmental science & technology2024

Unbound Fractions of PFAS in Human and Rodent Tissues: Rat Liver a Suitable Proxy for Evaluating Emerging PFAS?

Sangwoo Ryu, Woodrow Burchett, Sam Zhang, Xuelian Jia, Seyed Mohamad Sadegh Modaresi, Juliana Agudelo Areiza, David Rodrigues, Hao Zhu, Elsie M Sunderland, Fabian Christoph Fischer and 1 more

Abstract read
In one paragraph

Article in Environmental science & technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sangwoo RyuDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881, United States.
Woodrow BurchettPharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Pfizer Incorporated, Groton, Connecticut 06340, United States.
Sam ZhangPharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Pfizer Incorporated, Groton, Connecticut 06340, United States.
Xuelian JiaDepartment of Chemistry and Biochemistry, Rowan University, Glassboro, New Jersey 08028, United States.
Seyed Mohamad Sadegh ModaresiDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881, United States.
Juliana Agudelo AreizaDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881, United States.
David RodriguesPharmacokinetics, Dynamics and Metabolism, Pfizer Worldwide Research & Development, Pfizer Incorporated, Groton, Connecticut 06340, United States.
Hao ZhuDepartment of Chemistry and Biochemistry, Rowan University, Glassboro, New Jersey 08028, United States.ORCID 0000-0002-3559-6129
Elsie M SunderlandHarvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts 02138, United States.ORCID 0000-0003-0386-9548
Fabian Christoph FischerDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881, United States.ORCID 0000-0002-9511-0506
Angela L SlittDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island 02881, United States.ORCID 0000-0002-0572-7001

Funding

Sources, Transport, Exposure & Effects of PFAS (STEEP) Center - RENEWALP42ES027706 · NIEHS · UNIVERSITY OF RHODE ISLAND · PI Rainer Lohmann · 2017 to 2026
$18.9M
Discovering Chemical Activity Networks-Predicting Bioactivity Based on StructureR35ES031709 · NIEHS · OREGON STATE UNIVERSITY · PI Robyn L Tanguay · 2021 to 2026
$5.2M
Integrated Transporter Elucidation CenterUC2HD113039 · NICHD · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI Lauren M Aleksunes, Dongeun Huh · 2023 to 2026
$4.5M
Mechanism-Driven Virtual Adverse Outcome Pathway Modeling for HepatotoxicityR01ES031080 · NIEHS · TULANE UNIVERSITY OF LOUISIANA · PI ZHU, HAO · 2020 to 2024
$2.3M
Virtual nanostructure simulation (VINAS) portalR01GM148743 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI Hao Zhu · 2023 to 2026
$1.1M
NICHD NIH HHS UC2 HD113039NIEHS NIH HHS P42 ES027706NIEHS NIH HHS R01 ES031080NIEHS NIH HHS R35 ES031709NIGMS NIH HHS R01 GM148743
6 · The paper itself

Abstract

Adverse health effects associated with exposures to perfluoroalkyl and polyfluoroalkyl substances (PFAS) are a concern for public health and are driven by their elimination half-lives and accumulation in specific tissues. However, data on PFAS binding in human tissues are limited. Accumulation of PFAS in human tissues has been linked to interactions with specific proteins and lipids in target organs. Additional data on PFAS binding and unbound fractions (

Indexed as

FluorocarbonsLiverAnimalsHumansMiceRatsTissue DistributionFluorocarbonsequilibrium dialysisPFASspecies correlationtissue bindingunbound fractions

Identifiers

PMID39161261
PMCPMC11825104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.